News

April 10th, 2025: Panosome is one of the winners of the 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐢𝐳𝐞 𝐨𝐟 𝐆𝐞𝐫𝐦𝐚𝐧 𝐁𝐢𝐨𝐑𝐞𝐠𝐢𝐨𝐧𝐬 at this year's German Biotech Days event in Heidelberg, taking home the Audience Award for presenting our VAST platform an

April 10th, 2025: Panosome is one of the winners of the 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐢𝐳𝐞 𝐨𝐟 𝐆𝐞𝐫𝐦𝐚𝐧 𝐁𝐢𝐨𝐑𝐞𝐠𝐢𝐨𝐧𝐬 at this year's German Biotech Days event in Heidelberg, taking home the Audience Award for presenting our VAST platform and oncology results.

June 29, 2024, Heidelberg: Panosome GmbH together with our partner the German Cancer Research Center received a second KMU Innovativ award for 2.7 million EURO research funding (with 1.8 million EURO to Panosome in non-dilutive funding) to advance ou

June 29, 2024, Heidelberg: Panosome GmbH together with our partner the German Cancer Research Center received a second KMU Innovativ award for 2.7 million EURO research funding (with 1.8 million EURO to Panosome in non-dilutive funding) to advance our work in developing a treatment for brain cancer.

May 21, 2024, Heidelberg: Panosome GmbH together with our partner the German Cancer Research Center received a 2 million EURO research award (KMU Innovativ, with 1.5 million EURO in non-dilutive funding to Panosome) to advance our work in developing

May 21, 2024, Heidelberg: Panosome GmbH together with our partner the German Cancer Research Center received a 2 million EURO research award (KMU Innovativ, with 1.5 million EURO in non-dilutive funding to Panosome) to advance our work in developing a treatment for pancreatic cancer. Secretary of State, Dr. Jens Brandenburg, visited Panosome GmbH to personally hand over the grant notice. To mark the occasion, a syndicate from members of Encourage Ventures e.V. has announced their commitment to invest in Panosome.

January 2023: VAST platform reported in a comprehensive paper in Cell Reports.

January 2023: VAST platform reported in a comprehensive paper in Cell Reports.

October 2022: Panosome in collaboration with the German Cancer Center receives an ERC Proof of Concept grant to optimize nanoVAST, a VAST-coated trypanosome non- viral LNP for precision payload delivery of genome editors and other cargo.

October 2022: Panosome in collaboration with the German Cancer Center receives an ERC Proof of Concept grant to optimize nanoVAST, a VAST-coated trypanosome non- viral LNP for precision payload delivery of genome editors and other cargo.

April 2022: CSO of Panosome and Hepione Dr. Joey Verdi is an invited speaker at the 3rd RNA Editing Summit to present nanoVAST.

April 2022: CSO of Panosome and Hepione Dr. Joey Verdi is an invited speaker at the 3rd RNA Editing Summit to present nanoVAST.

June 21, 2021: Founder and CSO Dr. Nina Papavasiliou receives DKFZ Innovation Award for her translational efforts with the VAST platform and Panosome.

June 21, 2021: Founder and CSO Dr. Nina Papavasiliou receives DKFZ Innovation Award for her translational efforts with the VAST platform and Panosome.

November 20, 2020: Founder and CSO Dr. Nina Papavasiliou presents the VAST technology at the 2020 BioRN Annual Conference in Heidelberg. Image link to her recorded presentation.

November 20, 2020: Founder and CSO Dr. Nina Papavasiliou presents the VAST technology at the 2020 BioRN Annual Conference in Heidelberg. Image link to her recorded presentation.

December 17, 2020: Panosome GmbH registered in Heidelberg, Germany.

December 17, 2020: Panosome GmbH registered in Heidelberg, Germany.

September 23, 2020: NIH SBIR grant awarded to VAST sublicensee Hepione Therapeutics for "A Fentanyl Vaccine to Prevent Overdose."

September 23, 2020: NIH SBIR grant awarded to VAST sublicensee Hepione Therapeutics for "A Fentanyl Vaccine to Prevent Overdose."